The revenue beat is partially driven by non-recurring license milestones ($2.5M Théa, $1.25M Everest), not core product sales growth. Monitor the telehealth channel's impact on prescription volumes in Q3 and whether the 5-pack annual refill rate materializes. The heavy SG&A spend ($39.4M in Q2 alone) suggests cash runway of ~2 years at current burn, but profitability remains distant.
Price Chart
Executive Summary
LENZ Therapeutics reported Q2 2026 revenue of $5.5M (beating $2.4M consensus) and EPS of -$1.02 (beating -$1.07 consensus), driven by $1.7M in VIZZ product sales and $3.8M in license revenue. The net loss widened to $31.9M from $14.9M a year ago due to heavy commercial launch spending, but the company highlighted encouraging early refill behavior and a new telehealth channel launched in July 2026. Despite the revenue beat, the stock's historical pattern shows poor follow-through on bullish reads, and the widening loss and cash burn temper the positive surprise.
Key Financial Metrics
Key Facts
- Q2 2026 total revenue $5.5M vs consensus $2.4M (beat)
- EPS -$1.02 vs consensus -$1.07 (5.1% beat)
- Product sales $1.7M (~27,000 packs sold), up 9% QoQ
- License revenue $3.8M included $2.5M milestone from Théa and $1.25M from Everest sublicense
- Net loss widened to $31.9M from $14.9M YoY, driven by $39.4M SG&A (vs $12.8M)
- Cash and securities $220.0M as of June 30, 2026
- Telehealth channel launched July 2026; nationwide TV campaign with Sarah Jessica Parker began
- Over 60% of ePharmacy patients have purchased multiple monthly packs; early cohorts tracking to 5 packs/year
- MAA submitted in UK (April 2026), Canada (June 2026), Saudi Arabia (July 2026); partnership in Australia/NZ signed
Financial Impact
Revenue beat of ~$3.1M vs consensus; net loss $31.9M vs $14.9M YoY; cash burn of ~$47M in H1 2026
Risk Factors
- Heavy commercial spending ($39.4M SG&A) is unsustainable relative to $1.7M product sales
- License revenue is lumpy and non-recurring; core product sales growth is modest (9% QoQ)
- Competition from other presbyopia treatments (e.g., pilocarpine-based drops) could limit VIZZ adoption
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3343147 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | Press Release | $3.25 | awaiting T+1 | — | $3.14 (−3.23%) |
Oct 21, 2026 5d ago | SC 13G/A | $3.25 $3.16 | ▼ −2.77% | ▼ −2.25% | $3.14 (−3.23%) |
Aug 11, 2026 10w ago | Press Release | $5.04 $4.60 | ▼ −8.73% | ▼ −9.43% | $3.14 (−37.60%) |
Jul 2, 2026 16w ago | 8-K | $5.89 $5.60 | ▼ −4.92% | ▼ −5.80% | $3.14 (−46.60%) |
Jun 11, 2026 19w ago | Institutional Cluster | $6.50 $6.77 | ▲ +4.15% | ▲ +3.61% | $3.14 (−51.62%) |
Jun 7, 2026 20w ago | Press Release | $6.72 $6.79 | ▲ +1.04% | ▲ +1.34% | $3.14 (−53.20%) |
May 11, 2026 24w ago | 8-K | $7.91 $7.91 | · 0.00% | ▼ −0.54% | $3.14 (−60.24%) |
May 4, 2026 25w ago | Press Release | $9.28 $9.07 | ▼ −2.26% | ▼ −3.06% | $3.14 (−66.11%) |
Mar 24, 2026 30w ago | Press Release | $9.03 $9.07 | ▲ +0.44% | ▼ −0.12% | $3.14 (−65.17%) |
Feb 28, 2026 34w ago | Institutional Cluster | $13.68 $13.15 | ▼ −3.87% | ▼ −2.96% | $3.14 (−77.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers